SG Cowen Lowers Trimeris to 'Market Perform'

Analyst Yaron Werber cited a survey that indicates a limited demand for the company's AIDS drug

SG Cowen downgraded Trimeris (TRMS ) to market perform from outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.